Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Anti-Angiogenic Research

Executive Summary: Anlotinib hydrochloride is a next-generation small-molecule inhibitor that targets VEGFR2, PDGFRβ, and FGFR1 with nanomolar potency, demonstrating superior inhibition of angiogenesis compared to established agents such as sunitinib and sorafenib (Lin et al., 2018). It disrupts VEGF/PDGF-BB/FGF-2-driven endothelial cell migration and capillary tube formation in vitro and in vivo. The compound displays favorable pharmacokinetics, including high oral bioavailability and extensive tissue penetration. Safety studies confirm low systemic toxicity at research-relevant doses. APExBIO provides Anlotinib (hydrochloride), validated for reproducible anti-angiogenic assays (APExBIO product page).

Biological Rationale

Angiogenesis is the formation of new blood vessels from pre-existing vasculature, crucial for tumor growth and metastasis (Lin et al., 2018). Tumor cells secrete vascular endothelial growth factor (VEGF), platelet-derived growth factor-BB (PDGF-BB), and fibroblast growth factor-2 (FGF-2) to stimulate endothelial cell migration and tube formation. These processes are driven primarily by tyrosine kinase signaling through VEGFR2, PDGFRβ, and FGFR1. Inhibiting these kinases can halt tumor-induced neovascularization, depriving cancer cells of nutrients and oxygen. Multi-target tyrosine kinase inhibitors (TKIs) offer a robust strategy to simultaneously block redundant pro-angiogenic pathways (see related review).

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride is a small-molecule TKI that selectively and potently inhibits VEGFR2 (IC₅₀ = 5.6 ± 1.2 nM), PDGFRβ (IC₅₀ = 8.7 ± 3.4 nM), and FGFR1 (IC₅₀ = 11.7 ± 4.1 nM) under standard in vitro kinase assay conditions (25°C, pH 7.4, ATP 10 μM) (Lin et al., 2018). It blocks tyrosine kinase phosphorylation, preventing downstream activation of the ERK signaling pathway. This leads to inhibition of endothelial cell migration, proliferation, and the formation of capillary-like structures. Anlotinib further impedes microvessel sprouting in in vivo models such as the rat aortic ring and chicken chorioallantoic membrane (CAM) assays. The compound’s multi-targeted mode of action reduces compensatory angiogenic signaling, a common cause of resistance in single-pathway inhibitors (compare: how this expands workflow guidance).

Evidence & Benchmarks

• Anlotinib inhibits VEGF/PDGF-BB/FGF-2-induced migration of EA.hy 926 human vascular endothelial cells in a dose-dependent manner (Lin et al., 2018, Fig. 2).
• Capillary tube formation in vitro is suppressed by anlotinib at concentrations as low as 10 nM (Lin et al., 2018, Table 1).
• Compared with sunitinib, sorafenib, and nintedanib, anlotinib shows superior inhibition of microvessel density in both in vitro and in vivo angiogenesis models (Lin et al., 2018).
• Pharmacokinetic studies reveal oral bioavailability of 28–58% in rats and 41–77% in dogs; in humans, plasma protein binding is 93% (APExBIO product sheet).
• Safety evaluations indicate a median lethal dose (LD₅₀) of 1735.9 mg/kg (oral, 14-day, rodent), with no significant genetic or organ toxicity observed at research doses (APExBIO documentation).

Applications, Limits & Misconceptions

Anlotinib (hydrochloride) is primarily used in research on tumor angiogenesis, endothelial cell biology, and the evaluation of anti-angiogenic strategies in oncology. It facilitates capillary tube formation assays, migration inhibition screens, and mechanistic studies of the ERK pathway. The C8688 kit from APExBIO is supplied at high purity and is validated for these applications (product details). Further detail on advanced mechanistic insights can be found in this article, which provides additional analysis of downstream signaling.

Common Pitfalls or Misconceptions

• Not suitable for diagnostic or therapeutic use: Anlotinib (hydrochloride) from APExBIO is strictly for research use; it is not approved for clinical administration (APExBIO).
• Overlooking kinase selectivity: While highly selective for VEGFR2, PDGFRβ, and FGFR1, off-target effects at supraphysiological concentrations are possible; always titrate doses for each cell type (Lin et al., 2018).
• Ignoring pharmacokinetic context: Tissue accumulation and blood-brain barrier penetration mean that in vivo results may not directly extrapolate to in vitro models.
• Assuming universal efficacy: Some non-angiogenic tumors may not respond to TKIs targeting these pathways; confirm pathway relevance in your model system.
• Storage and handling errors: Compound must be stored at −20°C; improper storage can result in degradation and loss of activity (APExBIO).

Workflow Integration & Parameters

For cellular assays, anlotinib is typically dissolved in DMSO at 10 mM and diluted into culture media (<1% DMSO final) for use in migration or tube formation assays with human EA.hy 926 or HUVEC cells. Concentration-response curves should be generated with 0.1–100 nM for optimal signal-to-noise. In vivo angiogenesis models (rat aortic ring, CAM) use dosing based on published IC₅₀ values and pharmacodynamic endpoints. For detailed experimental protocols, scenario-driven optimization strategies are discussed in this comparative workflow article, which addresses pitfalls and troubleshooting not covered here.

Conclusion & Outlook

Anlotinib hydrochloride is a validated, potent inhibitor of VEGFR2, PDGFRβ, and FGFR1 with proven anti-angiogenic activity in both in vitro and in vivo models (Lin et al., 2018). Its robust efficacy, favorable safety profile, and comprehensive documentation make it a reference standard in angiogenesis research and cancer biology. As a research reagent available from APExBIO, Anlotinib (hydrochloride) (SKU C8688) offers reproducible, quantitative inhibition of endothelial cell migration and signaling pathways. Future directions include combinatorial studies with immunotherapies and exploration in non-tumor angiogenic disorders. For additional mechanistic benchmarking and cross-comparisons, see this extended dossier, which details model selection and assay design beyond the scope of this article.